Signaturefd LLC Acquires 742 Shares of Inhibrx, Inc. (NASDAQ:INBX)

Signaturefd LLC increased its position in shares of Inhibrx, Inc. (NASDAQ:INBX) by 4,637.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 758 shares of the company’s stock after purchasing an additional 742 shares during the period. Signaturefd LLC’s holdings in Inhibrx were worth $29,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in INBX. Hennion & Walsh Asset Management Inc. lifted its holdings in Inhibrx by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 27,731 shares of the company’s stock worth $509,000 after purchasing an additional 13,098 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Inhibrx during the 3rd quarter worth approximately $232,000. Swiss National Bank lifted its holdings in Inhibrx by 2.1% during the 3rd quarter. Swiss National Bank now owns 57,600 shares of the company’s stock worth $1,057,000 after purchasing an additional 1,200 shares during the last quarter. Citigroup Inc. lifted its holdings in Inhibrx by 3.4% during the 3rd quarter. Citigroup Inc. now owns 49,244 shares of the company’s stock worth $904,000 after purchasing an additional 1,611 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in Inhibrx during the 3rd quarter worth approximately $7,964,000. 82.46% of the stock is owned by institutional investors and hedge funds.

Inhibrx Price Performance

Shares of NASDAQ INBX opened at $34.15 on Friday. The stock has a market capitalization of $1.79 billion, a PE ratio of -6.79 and a beta of 2.87. The company has a debt-to-equity ratio of 4.78, a current ratio of 5.24 and a quick ratio of 5.25. The business has a fifty day moving average price of $35.11 and a two-hundred day moving average price of $30.81. Inhibrx, Inc. has a fifty-two week low of $14.31 and a fifty-two week high of $39.79.

Inhibrx (NASDAQ:INBX) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.66). The company had revenue of $1.63 million during the quarter, compared to analyst estimates of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative return on equity of 590.78%. As a group, equities analysts predict that Inhibrx, Inc. will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

INBX has been the subject of several analyst reports. JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a report on Tuesday, January 23rd. Lifesci Capital cut Inhibrx from an “outperform” rating to a “market perform” rating in a report on Tuesday, January 23rd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.